Evotec's Waiting Game: Can New Deals Outweigh a Broken Promise?
Published on 08/06/2026 at 18:33 | Redaktion boerse-global.de
The numbers tell a brutal story. Evotec's share price has shed 36.18 percent since the start of the year, closing at 3.48 euros in the latest session — and the stock was still drifting lower in Thursday trading at 3.45 euros, down 0.75 percent. But beneath that surface-level decline sits a more complex picture: a company fighting on multiple fronts, signing new partnerships while simultaneously defending against speculation about its future ownership.
The July Reckoning
The turning point came on July 13, when the Hamburg-based drug discovery specialist issued a profit warning that reset expectations for the entire year. Preliminary first-half figures showed group revenue of roughly 300.1 million euros with adjusted EBITDA of approximately minus 42.7 million euros. More damaging was the guidance revision: full-year revenue expectations were slashed from 700 to 780 million euros down to 570 to 610 million euros, while the adjusted EBITDA outlook swung from breakeven-to-plus-40-million into a loss range of 70 to 105 million euros. Management blamed delays across several projects.
The deterioration wasn't sudden. First-quarter numbers had already revealed cracks — revenue fell 21.7 percent to 156.6 million euros, and the loss per share ballooned from minus 0.18 euros to minus 0.69 euros. The July warning merely formalized what the market had been sensing for months.
A Takeover Question Hangs in the Air
Complicating matters is the strategic intrigue surrounding the company's shareholder base. Private equity firm Triton Partners has been steadily increasing its stake and is reportedly exploring a full takeover, according to the Russian news agency AK&M. Talks with Evotec's management board are said to be underway, though no specifics on pricing or timing have emerged.
Should investors sell immediately? Or is it worth buying Evotec?
That speculation adds another layer of uncertainty to an already volatile situation. Investors are left weighing the possibility of a buyout against the operational reality of a company in the middle of a painful restructuring.
The Horizon Program and a New CFO
Evotec's response to its operational struggles has been the "Horizon" restructuring program, announced in March. The plan calls for consolidating the organization down to ten sites and achieving run-rate savings of approximately 75 million euros by the end of 2027. The cost-cutting drive gained a new face in May when Claire Hinshelwood replaced Paul Hitchin as chief financial officer — a leadership change that signals how seriously the company is taking its expense discipline.
The balance sheet offers some breathing room: liquidity stood at around 465.6 million euros as of June 30. That cushion buys time, but it doesn't mask the underlying operational strain.
Signs of Life on the Deal Front
Despite the gloomy financials, the business development engine hasn't stalled. On August 3, Niagen Bioscience selected Evotec as its partner for preclinical development of NB4168, a candidate in the healthy-aging space. More recently, the company announced a strategic research and development collaboration with Odyssey Therapeutics focused on AI-driven identification of drug candidates for autoimmune and inflammatory diseases, leveraging Evotec's platform.
Other operational developments include the late-June launch of "J.TRAIN" by subsidiary Just – Evotec Biologics, a solution for continuous biologics manufacturing at customer sites, and the introduction of the AI-powered Navan platform for travel, payments, and expense management — an internal efficiency project aligned with the broader cost-saving logic.
These announcements don't compensate for weak group numbers, but they demonstrate that the platform retains commercial appeal even as the company restructures.
What the Technicals Say
Market indicators reflect the tension. The 30-day decline stands at 31.40 percent, showing how forcefully the guidance cut continues to reverberate. The relative strength index sits at 28.6 in the latest reading — technically oversold territory, though analysts caution that such signals say nothing about fundamental recovery. The secondary source puts the RSI at 29.4, a marginal difference that doesn't change the picture: the stock is deeply stretched to the downside.
Evotec at a turning point? This analysis reveals what investors need to know now.
Analyst sentiment has been cautious but not entirely bearish. The average price target consensus stood at 5.40 euros at the end of July, supported by one buy rating and three hold recommendations. Whether that view persists may depend on the updated consensus expected around the time of the full half-year report.
The August 13 Test
All eyes now turn to August 13, when Evotec publishes its complete, audited half-year report alongside an analyst webcast. Investors will be looking for specifics on which projects caused the delays and how management plans to steer the cost base over the coming quarters. The next scheduled update — third-quarter figures — follows on November 5.
Until then, the stock remains caught between competing narratives. New collaborations with Odyssey Therapeutics and Niagen Bioscience suggest the platform still has pull. The Triton Partners speculation introduces the possibility of ownership change. But the lowered guidance serves as a stark reminder that the core business has yet to prove it can deliver on its original promises. The August 13 report may well determine which of these forces wins out in the months ahead.
Ad
Evotec Stock: New Analysis - 6 August
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
